The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

•We report 181 people with CF from 19 countries diagnosed with SARS-CoV-2.•Spectrum of outcomes observed was similar to that seen in the general population.•11 people were admitted to intensive care and 7 died.•Three of the people who died had received an organ transplant.•Lower lung function and having been transplanted may be linked to hospitalisation. With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.